Cognitive Changes in Perimenopause: What Clinicians Should Know

Cognitive complaints during perimenopause are not subjective exaggeration. Longitudinal data from the SWAN study and neuroimaging research confirm that measurable changes in processing speed, verbal memory, and attention occur during the menopausal transition, and that these changes are associated with fluctuating estrogen levels rather than aging alone.

For clinicians, the challenge is distinguishing these transient, hormone-associated cognitive shifts from early neurodegenerative processes, and knowing when reassurance is appropriate versus when further evaluation is warranted.

What the SWAN study found

The Study of Women's Health Across the Nation (SWAN) followed over 2,300 women longitudinally through the menopausal transition, conducting repeated cognitive assessments over more than a decade. The cognitive findings, published across multiple analyses, are consistent:

• Processing speed declined measurably during perimenopause relative to premenopausal baseline (Greendale et al., 2009)
• Verbal learning and memory showed a transient decline during late perimenopause that largely resolved in the postmenopausal period (Greendale et al., 2011)
• The cognitive dip was associated with the perimenopausal stage itself, not with chronological age, and persisted after controlling for mood, sleep, and vasomotor symptoms
• Importantly, cognitive performance generally recovered after the transition was complete, suggesting these changes are related to hormonal flux rather than permanent decline

The neurobiology: estrogen and the hippocampus

The mechanistic basis for perimenopause-related cognitive changes is well-established in neuroscience research. Estrogen receptors (particularly ER-alpha and ER-beta) are densely concentrated in brain regions critical for cognition:

Hippocampus

Estrogen modulates synaptic plasticity in the hippocampus, the brain region most critical for verbal memory and learning. Research by Weber et al. (2014) using functional MRI demonstrated that women in perimenopause showed altered hippocampal activation patterns during memory tasks compared to premenopausal controls, even when behavioral performance was maintained.

Prefrontal cortex

Estrogen influences dopaminergic and serotonergic signaling in the prefrontal cortex, which is essential for working memory, attention, and executive function. Fluctuating estrogen levels during perimenopause may disrupt these neurotransmitter systems.

Mosconi's neuroimaging findings

Lisa Mosconi and colleagues at Weill Cornell have published PET and MRI data showing that women in the menopausal transition exhibit reduced cerebral glucose metabolism (a marker of brain energy production) compared to premenopausal women. Their 2021 study in Scientific Reports found that brain glucose metabolism decreased by approximately 20% during perimenopause but partially recovered in the postmenopausal period, paralleling the cognitive trajectory observed in SWAN.

Distinguishing hormonal from neurodegenerative cognitive changes

This is the most clinically important question. When a 48-year-old patient reports brain fog and memory difficulties, is this perimenopausal or something else? Several features help differentiate:

Features suggesting hormonal etiology

• Onset coincides with menstrual irregularity or other perimenopausal symptoms
• Symptoms fluctuate (better some days, worse others) rather than progressively worsening
• Primarily affects verbal memory and processing speed rather than spatial navigation or recognition
• Patient retains insight into the changes and is often frustrated by them
• No functional impairment in activities of daily living
• Associated with sleep disruption, mood changes, or vasomotor symptoms

Features warranting further evaluation

• Progressive worsening over 6-12 months without fluctuation
• Getting lost in familiar places or difficulty with spatial tasks
• Difficulty with previously automatic tasks (following recipes, managing finances)
• Language impairment beyond word-finding difficulty (e.g., paraphasic errors)
• Family history of early-onset dementia
• Personality or behavioral changes noted by others
• Functional impairment in daily activities

Assessment approach

For clinicians evaluating cognitive complaints in perimenopausal patients, a structured approach improves both diagnostic accuracy and patient confidence:

1. Characterize the cognitive complaint. Use targeted questions: "Is it getting progressively worse, or does it come and go?" "Which is harder: remembering words, or remembering where you put things?" "Are you able to do everything you need to do, even if it feels harder?"
2. Screen for contributing factors. Sleep disturbance, depression, anxiety, and thyroid dysfunction all affect cognition and are more common during perimenopause. Treating these may resolve cognitive symptoms independent of hormonal status.
3. Consider brief cognitive screening. The Montreal Cognitive Assessment (MoCA) can identify patients who need formal neuropsychological evaluation. Scores below 26/30 warrant further investigation, though false positives are common.
4. Assess longitudinally. A single cognitive assessment has limited value. Repeated assessments over 3-6 months can distinguish fluctuating (hormonal) from progressive (potentially neurodegenerative) patterns.
5. Provide evidence-based reassurance. Patients are often terrified they are developing dementia. Sharing the SWAN data showing that perimenopause-related cognitive changes typically resolve after the transition is both accurate and therapeutic.

When to refer

Referral for formal neuropsychological evaluation or neurology consultation is appropriate when:

• Cognitive decline is progressive over 6+ months despite treatment of contributing factors
• Brief screening (MoCA) suggests impairment beyond expected perimenopausal changes
• There is functional impairment in daily activities
• The patient has significant risk factors (family history, cardiovascular risk, head injury history)
• The clinician or patient remains uncertain after initial evaluation and follow-up

The bottom line

Perimenopause-related cognitive changes are neurobiologically grounded, measurable, and in most women, transient. They represent a distinct clinical entity from neurodegenerative cognitive decline. Clinicians who understand this distinction can provide accurate assessment, appropriate reassurance, and timely referral when the pattern does not fit the expected hormonal trajectory.

The key clinical tool is longitudinal observation. A single assessment cannot distinguish fluctuating from progressive decline. Repeated measurement over time provides the diagnostic clarity that no single test can offer.